Merck starts Phase 3 trial of Ohtuvayre for COPD exacerbations
Tweet Send to a Friend
Merck (NYSE: MRK) has initiated ENHANCE-3, a Phase 3 randomized clinical trial evaluating Ohtuvayre (ensifentrine) for the prevention of chronic ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE




